Prevalence and outcomes of extrahepatic primary malignancy associated with Hepatocellular Carcinoma in a Korean population

Table 3 Locations and pathologic TNM stages of 33 EHPM patients

Case number	EHPM site	EHPM group^a	pTNM stage^†				Follow up or survival duration (months)	Cause of death^b
Case number	EHPM site	EHPM group^a	T	N	M	Stage	Follow up or survival duration (months)	Cause of death^b
1	Rectum	S	3	0	0	IIA	118
2^*	Breast	S	1	0	0	IA	4	H
3^*	Stomach	S	3	3	1	IV	10	E
4^*	Stomach	S	1	0	0	IA	21	E and O
5	Breast	S	1	0	0	IA	53
6^*	Kidney	S	1	0	0	I	0	H
7^*	Rectum	S	3	2	0	IIIB	12	H
8	Esophagus	S	1	0	0	IA	52
9	Kidney	S	1	0	0	I	51
10	Colon	S	3	0	0	IIA	48
11	Stomach (MALToma)	S				IEA(Ann Arbor)	47
12	Colon	S	3	0	0	IIA	32
13	Colon	S	3	0	0	IIA	28
14	Retroperitoneum	S	2b	0	0	Ib	35
15^*	Multiple myeloma	S				III(ISS)	23	E
16	Stomach	S	is	0	0	0	17
17^*	Rectum	S	3	1	0	IIIB	4	O
18^*	Rectum	S	4b	2b	0	IIIC	3	H and E
19^*	Stomach	M	3	0	0	IIA	16	H
20^*	Kidney	P	NA				18	H
21	Pancreas	M	3	1	0	IIIB	55
22	Prostate	M	3	0	0	III	74
23	Breast	P	2	0	0	IIA	46
24	Colon	P	2	0	0	I	27
24	Stomach	P	1b	0	0	IA	27
25	Colon	M	3	0	1	IVA	38
26	Colon	M	NA				24
27	Thyroid	M	3	1a	0	III	29
28	CBD	M	4	1	0	III	109
29	Stomach	P	1	0	0	IA	17
30	Stomach	P	NA				0
31^*	Breast	P	1	0	0	IA	1	O
32	Stomach	P	1	0	0	IA	20
33	Bladder	M.	1	0	0	I	100

CBD, common bile duct; EHPM, extrahepatic primary malignant neoplasm; HCC, hepatocellular carcinoma; is, in situ; NA, not applicable; pTNM stage, pathologic TNM stage.
^aM, metachronous group; P, prior group; S, synchronous group.
^bH, HCC related; E, EHPM related; O, Others.
^†Based on AJCC 7th edition, except Ann Arbor Staging for gastric lymphoma (MALToma) and ISS (International Staging System) for multiple myeloma.
*Patient who expired.

ISSN: 1471-2407